Mesoblast has completed treatment of 300 patients in its pivotal Phase 3 trial for rexlemestrocel-L, targeting chronic low back pain due to degenerative disc disease, with topline results expected mid-2027.
- Phase 3 trial reaches full enrollment of 300 patients
- Rexlemestrocel-L targets chronic low back pain with single injection
- FDA RMAT designation enables priority review pathway
- Trial includes opioid cessation and quality of life endpoints
- Potential blockbuster market with US$10 billion peak revenue
Pivotal Trial Completes Patient Treatment Milestone
Mesoblast Limited (ASX:MSB) has achieved a crucial milestone in its Phase 3 MSB-DR004 trial by treating at least 300 patients with rexlemestrocel-L, its allogeneic cellular therapy for chronic low back pain (CLBP) associated with degenerative disc disease (DDD). This randomized, placebo-controlled study aims to confirm durable pain reduction from a single intra-discal injection, building on positive results from the prior MSB-DR003 trial.
Chief Executive Silviu Itescu emphasised that meeting the enrollment target ensures the trial is well powered to demonstrate efficacy. Meanwhile, commercial manufacturing is progressing to enable swift regulatory filings and potential market launch following data readout, expected in mid-2027 after patients complete 12 months of follow-up.
Addressing a Large Unmet Medical Need
CLBP caused by inflammation and degenerative disc disease affects over 7 million people in the US alone, representing a significant healthcare burden. The condition is a leading cause of disability, particularly in adults under 45, and is closely linked to opioid use, accounting for approximately half of prescription opioid consumption in the country. Mesoblast's therapy aims not only to reduce pain but also to improve function, quality of life, and reduce reliance on opioids.
The trial's primary endpoint is a significant reduction in pain at 12 months compared to sham controls. Secondary endpoints include functional improvements and opioid cessation, critical factors given the ongoing opioid epidemic. Rexlemestrocel-L's FDA Regenerative Medicine Advanced Therapy (RMAT) designation provides a regulatory advantage, offering benefits such as rolling review and eligibility for priority review upon Biologics License Application (BLA) submission.
Commercial and Regulatory Outlook
Mesoblast projects potential peak year revenues exceeding US$10 billion for rexlemestrocel-L in CLBP, assuming modest market penetration. The company is concurrently scaling up commercial manufacturing to meet anticipated demand. The RMAT designation streamlines the regulatory pathway, potentially accelerating time to market if the trial confirms efficacy and safety.
Mesoblast's broader cell therapy portfolio includes Ryoncil®, the first FDA-approved mesenchymal stromal cell therapy for pediatric steroid-refractory acute graft-versus-host disease, which recently posted strong revenue growth with US$115 million annual revenue. This underscores the company's growing commercial footprint as it advances its pipeline.
Intellectual Property and Manufacturing Scale
The company holds a robust intellectual property portfolio with over 1,000 patents and applications protecting its mesenchymal stromal cell technologies through at least 2044. Its proprietary manufacturing processes enable industrial-scale production of off-the-shelf cellular medicines, designed for global patient access.
As Mesoblast advances rexlemestrocel-L through this pivotal trial, the biotech sector will be watching closely to see if this novel approach can deliver on its promise to alleviate a widespread and debilitating condition while addressing the opioid crisis.
Bottom Line?
The next 12 months will be critical as Mesoblast awaits trial results that could unlock a major new therapy for chronic low back pain with significant commercial and societal impact.
Questions in the middle?
- Will rexlemestrocel-L demonstrate statistically and clinically meaningful pain reduction at 12 months?
- How effectively will the therapy reduce opioid dependence among trial participants?
- What regulatory feedback will Mesoblast receive following topline data and BLA submission?